Discontinued — last reported Q3 '22
Berkshire Hathaway Acquisitions increased by 70.0% to $34.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric declined by 15.0%, from $40.00M to $34.00M. Over 3 years (FY 2021 to FY 2024), Acquisitions shows a downward trend with a -4.6% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $57.00M | $100.00M | $252.00M | $34.00M | $69.00M | $80.00M | $10.41B | $7.63B | $887.00M | $48.00M | $40.00M | $327.00M | $15.00M | $20.00M | $34.00M |
| QoQ Change | — | +75.4% | +152.0% | -86.5% | +102.9% | +15.9% | >999% | -26.7% | -88.4% | -94.6% | -16.7% | +717.5% | -95.4% | +33.3% | +70.0% |
| YoY Change | — | — | — | — | +21.1% | -20.0% | >999% | >999% | >999% | -40.0% | -99.6% | -95.7% | -98.3% | -58.3% | -15.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.